BeOne Medicines (ONC) Gross Margin (2017 - 2026)
BeOne Medicines (ONC) reported Gross Margin of 88.95% for Q1 2026, up 372.0% year-over-year from 18.85% in Q1 2025, and down 1.7% on a QoQ basis from 90.49% in Q4 2025.
BeOne Medicines (ONC) has 10 years of Gross Margin data on file, last reported at 88.95% in Q1 2026.
- Quarterly Gross Margin rose 372.0% year-over-year to 88.95% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 88.31% (up 350.0% YoY) and the FY2025 annual result came in at 87.49%, up 308.0% from the prior year.
- Gross Margin declined to 88.95% in Q1 2026 per ONC's latest filing, from 90.49% in the prior quarter.
- Across five years, Gross Margin topped out at 90.49% in Q4 2025 and bottomed at 78.72% in Q1 2022.
- The 5-year median for Gross Margin is 83.87% (2023), against an average of 84.17%.
- The widest annual swing landed in 2022, when Gross Margin plunged 1588 bps; it then jumped 742 bps in 2023.
- Tracing ONC's Gross Margin over 5 years: stood at 80.66% in 2022, then advanced by 3 bps to 83.32% in 2023, then increased by 3 bps to 85.76% in 2024, then advanced by 6 bps to 90.49% in 2025, then dropped by 2 bps to 88.95% in 2026.
- Per Business Quant, the three latest ONC Gross Margin figures stand at 88.95% (Q1 2026), 90.49% (Q4 2025), and 86.09% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 79.04% |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 86.85% |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 91.79% |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 82.22% |
| 10 | BeOne Medicines | - | - | 1.35 Bn | 88.95% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 88.95% |
| Dec 31, 2025 | 90.49% |
| Sep 30, 2025 | 86.09% |
| Jun 30, 2025 | 87.49% |
| Mar 31, 2025 | 85.23% |
| Dec 31, 2024 | 85.76% |
| Sep 30, 2024 | 82.98% |
| Jun 30, 2024 | 85.13% |
| Mar 31, 2024 | 83.38% |
| Dec 31, 2023 | 83.32% |
| Sep 30, 2023 | 87.67% |
| Jun 30, 2023 | 83.87% |
| Mar 31, 2023 | 81.74% |
| Dec 31, 2022 | 80.66% |
| Sep 30, 2022 | 80.25% |
| Jun 30, 2022 | 79.16% |
| Mar 31, 2022 | 78.72% |
| Dec 31, 2021 | 77.31% |
| Sep 30, 2021 | 77.03% |
| Jun 30, 2021 | 75.82% |
| Mar 31, 2021 | 94.61% |
| Dec 31, 2020 | 78.94% |
| Sep 30, 2020 | 76.81% |
| Jun 30, 2020 | 78.20% |
| Mar 31, 2020 | 72.82% |
| Dec 31, 2019 | 68.39% |
| Sep 30, 2019 | 59.90% |
| Jun 30, 2019 | 88.11% |
| Mar 31, 2019 | 80.39% |
| Dec 31, 2018 | 84.33% |
| Sep 30, 2018 | 83.94% |
| Jun 30, 2018 | 88.15% |
| Mar 31, 2018 | 86.02% |
| Dec 31, 2017 | 83.33% |
| Sep 30, 2017 | 99.12% |